Anzeige
Mehr »
Login
Dienstag, 22.04.2025 Börsentäglich über 12.000 News von 692 internationalen Medien
Der Megatrend 2025: Die unterschätzte Chance im Uranmarkt - was diese Aktie JETZT interessant macht!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1J7EB | ISIN: FR0011341205 | Ticker-Symbol: 5NR
Tradegate
22.04.25
16:27 Uhr
2,950 Euro
-0,055
-1,83 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
NANOBIOTIX SA Chart 1 Jahr
5-Tage-Chart
NANOBIOTIX SA 5-Tage-Chart
RealtimeGeldBriefZeit
2,9602,99017:33
2,9602,99017:30

Aktuelle News zur NANOBIOTIX Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
14.04.Nanobiotix S.A.: Voting Rights and Shares Capital of the Company2
10.04.Nanobiotix S.A. - 6-K, Report of foreign issuer2
04.04.Guggenheim cuts Nanobiotix stock target to $8, maintains buy4
02.04.Nanobiotix GAAP EPS of -€1.441
02.04.Nanobiotix S.A. - 20-F, Annual and transition report of foreign private issuers2
02.04.Nanobiotix S.A.: NANOBIOTIX Provides Business Update and Reports Full Year 2024 Financial Results97Global development program for JNJ-1900 (NBTXR3) proceeding as planned, with opportunity to address one of the largest untapped markets in oncology through lead programs in head and neck cancer and...
► Artikel lesen
31.03.Nanobiotix S.A.: NANOBIOTIX to Announce Fourth Quarter and Full Year 2024 Operational and Financial Update on April 2, 20251
NANOBIOTIX Aktie jetzt für 0€ handeln
27.03.Nanobiotix reports promising NSCLC treatment study results1
27.03.Nanobiotix S.A. - 6-K, Report of foreign issuer1
27.03.Nanobiotix S.A.: Nanobiotix Announces First Data From the Completed Dose Escalation Part of a Phase 1 Study Evaluating NBTXR3 (JNJ-1900) as a 2L+ Therapy for Patients With Locally Advanced NSCLC276Data show favorable safety and confirm injection feasibility in 12 patients with locally advanced NSCLC amenable to re-irradiation for whom prior lines of therapy have failedA preliminary review of...
► Artikel lesen
18.03.Cancer-Focused Nanobiotix Adjusts $2.7 Billion Johnson & Johnson Agreement To Strengthen Finances And Relieve Funding Burden3
18.03.Nanobiotix tweaks J&J licensing deal for phase 3 cancer drug to eke out cash13
17.03.Nanobiotix S.A.: NANOBIOTIX Strengthens Financial Position Through Amendment of Global Licensing Agreement for JNJ-1900 (NBTXR3) and Extends Cash Visibility to Mid-2026127PARIS and CAMBRIDGE, Mass., March 17, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO -- NASDAQ: NBTX - the "Company''), a late-stage clinical biotechnology company pioneering disruptive nanotherapeutic...
► Artikel lesen
13.03.Nanobiotix S.A.: Voting Rights and Shares Capital of the Company2
13.03.Nanobiotix S.A. - 6-K, Report of foreign issuer1
12.02.Nanobiotix S.A.: Voting Rights and Shares Capital of the Company1
12.02.Nanobiotix S.A. - 6-K, Report of foreign issuer-
29.01.Nanobiotix S.A. - 6-K, Report of foreign issuer-
21.01.Nanobiotix Stock Gains as Dosing Begins in Mid-Stage NSCLC Study1
21.01.Nanobiotix S.A. - 6-K, Report of foreign issuer5
Seite:  Weiter >>
35 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1